Retrophin Up 40% On Kidney Disease Drug Trial, Shkreli Still Wants His $25+ Million 'Hogan Reward'

By: via Benzinga
Martin Shkreli, the so-called "most hated man on the Internet" is making news again. Retrophin Inc (NASDAQ: RTRX), a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.